ScinnoHub, a pharmaceutical company based in Chengdu, focuses on the development of innovative small-molecule drugs and precision therapeutic platforms with broad pipelines covering therapeutic areas, including cancer, autoimmune diseases, as well as targeted radioligand therapy and RNA splicing technologies. We strive to address unmet medical needs and develop innovative treatments that will benefit patients.
Our multidisciplinary research team consists of over 80 scientists, including scientists in our leadership team who have over 20-year overseas experience in medicinal chemistry, molecular biology, clinical science and translational medicine.
We are inspired by the unique features of hummingbirds, the smallest bird species in the world, which are typically less than 2.0 g (0.07 ounce) by weight and 5 cm (2.0 inch) by length. Remarkably, hummingbirds are capable of hovering in the air and migrating as far as 6,200 km (3,900 miles). Through in-house discovery and proactive collaborations with global renowned partners, we are accelerating the development and delivery of breakthrough medicines to patients around the world. We believe that drug discovery resembles the spirit of hummingbird migration calling for talents, dedication, ambition and perseverance.